- Home
- Europe Pterygium Drug Market
Europe Pterygium Drug Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-388 | No of pages: 223 | Format:
The Europe pterygium drug market is projected to register a substantial CAGR of 4.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Europe Pterygium Drug Market, By Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (Russia, Spain, Turkey, Germany, Italy, United Kingdom, France, Hungary, Austria, Switzerland, Netherlands, Poland, Ireland, Norway, Lithuania, Rest of Europe) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Europe pterygium drugs market are:
Rising incidences and prevalence of ophthalmic disorders
Rising geriatric population
Market Players:
Some of the major players operating in the Europe pterygium drug market are:
Johnson & Johnson Services, Inc.
Novartis AG
Akorn Operating Company LLC
Bausch & Lomb Incorporated
AbbVie Inc.
Prestige Consumer Healthcare Inc.
Tha Laboratories
SAGER PHARMA
Bayer AG
Zydus Group
Similasan Corporation
Alcon
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
1.3 OVERVIEW OF EUROPE PTERYGIUM DRUG MARKET 37
1.4 CURRENCY AND PRICING 39
1.5 LIMITATIONS 39
1.6 MARKETS COVERED 39
2 EUROPE PTERYGIUM DRUG MARKET: SEGMENTATION 43
2.1 MARKETS COVERED 43
2.2 GEOGRAPHICAL SCOPE 44
2.3 YEARS CONSIDERED FOR THE STUDY 45
2.4 DBMR TRIPOD DATA VALIDATION MODEL 46
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 49
2.6 MULTIVARIATE MODELLING 50
2.7 CLASS SEGMENT LIFELINE CURVE 50
2.8 DBMR MARKET POSITION GRID 51
2.9 VENDOR SHARE ANALYSIS 52
2.10 MARKET END USER COVERAGE GRID 53
2.11 SECONDARY SOURCES 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 59
4.1 PESTEL'S MODEL 60
4.2 PORTER'S 5 FORCES 61
4.3 EUROPE PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES 62
5 EPIDEMIOLOGY 63
6 PIPELINE ANALYSIS 64
7 EUROPE PTERYGIUM DRUG MARKET: REGULATIONS 65
7.1 REGULATION IN THE U.S. 65
7.2 REGULATION IN EUROPE: 66
7.3 REGULATIONS IN CHINA: 66
7.4 REGULATIONS IN INDIA: 67
7.5 RELEVANT ACTS FOR THIS FRAMEWORK: 67
8 MARKET OVERVIEW 68
8.1 DRIVERS 70
8.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS 70
8.1.2 RISE IN GERIATRIC POPULATION 70
8.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES 71
8.2 RESTRAINTS 72
8.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION 72
8.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS 72
8.3 OPPORTUNITIES 73
8.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES 73
8.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 73
8.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES 74
8.4 CHALLENGES 75
8.4.1 STRINGENT RULES & REGULATIONS 75
8.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS 76
9 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE 77
9.1 OVERVIEW 78
9.2 PROGRESSIVE PTERYGIUM 81
9.3 ATROPHIC PTERYGIUM 81
10 EUROPE PTERYGIUM DRUG MARKET, BY STAGES 83
10.1 OVERVIEW 84
10.2 STAGE 2 87
10.3 STAGE 3 87
10.4 STAGE 1 88
10.5 STAGE 4 89
11 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT 90
11.1 OVERVIEW 91
11.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS 94
11.2.1 DEMULCENT 95
11.2.2 EMOLLIENTS 95
11.3 STEROID EYE DROPS 95
11.3.1 KETONE STEROIDS 96
11.3.1.1 PREDNOSOLONE 97
11.3.1.2 DEXAMETHASONE 97
11.3.1.3 FLUROMETHOLONE 97
11.3.1.4 OTHERS 97
11.3.2 ESTER STEROID (LOTERPREDNOL) 97
12 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION 98
12.1 OVERVIEW 99
12.2 EYE DROPS 102
12.2.1 EYE DROPS WITH PRESERVATIVES 102
12.2.2 PRESERVATIVE-FREE EYE DROPS 102
12.3 EYE OINTMENTS 103
12.4 OTHERS 103
13 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE 105
13.1 OVERVIEW 106
13.2 PRESCRIPTION 109
13.3 OVER THE COUNTER (OTC) 109
14 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE 111
14.1 OVERVIEW 112
14.2 GERIATRIC 115
14.3 ADULTS 115
15 EUROPE PTERYGIUM DRUG MARKET, BY END USER 117
15.1 OVERVIEW 118
15.2 HOSPITALS 121
15.3 SPECIALTY CLINICS 121
15.4 HOME HEALTHCARE 122
15.5 OTHERS 122
16 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL 124
16.1 OVERVIEW 125
16.2 RETAIL PHARMACIES 128
16.3 HOSPITAL PHARMACIES 128
16.4 ONLINE PHARMACIES 129
16.5 OTHERS 129
17 EUROPE PTERYGIUM DRUG MARKET, BY REGION 131
17.1 EUROPE 132
17.1.1 RUSSIA 141
17.1.2 SPAIN 144
17.1.3 TURKEY 147
17.1.4 GERMANY 150
17.1.5 ITALY 153
17.1.6 U.K. 156
17.1.7 FRANCE 159
17.1.8 HUNGARY 162
17.1.9 AUSTRIA 165
17.1.10 SWITZERLAND 168
17.1.11 NETHERLANDS 171
17.1.12 POLAND 174
17.1.13 IRELAND 177
17.1.14 NORWAY 180
17.1.15 LITHUANIA 183
17.1.16 REST OF EUROPE 186
18 EUROPE PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE 187
18.1 COMPANY SHARE ANALYSIS: EUROPE 187
19 SWOT ANALYSIS 188
20 COMPANY PROFILES 189
20.1 ALCON 189
20.1.1 COMPANY SNAPSHOT 189
20.1.2 RECENT FINANCIALS 189
20.1.3 COMPANY SHARE ANALYSIS 190
20.1.4 PRODUCT PORTFOLIO 190
20.1.5 RECENT DEVELOPMENTS 191
20.2 ABBVIE INC. 192
20.2.1 COMPANY SNAPSHOT 192
20.2.2 REVENUE ANALYSIS 192
20.2.3 COMPANY SHARE ANALYSIS 193
20.2.4 PRODUCT PORTFOLIO 193
20.2.5 RECENT DEVELOPMENT 193
20.3 BAUSCH & LOMB INCORPORATED 194
20.3.1 COMPANY SNAPSHOT 194
20.3.2 REVENUE ANALYSIS 194
20.3.3 COMPANY SHARE ANALYSIS 195
20.3.4 PRODUCT PORTFOLIO 195
20.3.5 RECENT DEVELOPMENT 195
20.4 JOHNSON & JOHNSON SERVICES, INC. 196
20.4.1 COMPANY SNAPSHOT 196
20.4.2 REVENUE ANALYSIS 196
20.4.3 COMPANY SHARE ANALYSIS 197
20.4.4 PRODUCT PORTFOLIO 197
20.4.5 RECENT DEVELOPMENTS 197
20.5 BAYER AG 198
20.5.1 COMPANY SNAPSHOT 198
20.5.2 REVENUE ANALYSIS 198
20.5.3 COMPANY SHARE ANALYSIS 199
20.5.4 PRODUCT PORTFOLIO 199
20.5.5 RECENT DEVELOPMENTS 199
20.6 NOVARTIS AG 200
20.6.1 COMPANY SNAPSHOT 200
20.6.2 REVENUE ANALYSIS 200
20.6.3 PRODUCT PORTFOLIO 201
20.6.4 RECENT DEVELOPMENTS 201
20.7 SANTEN PHARMACEUTICAL CO., LTD. 202
20.7.1 COMPANY SNAPSHOT 202
20.7.2 RECENT FINANCIALS 202
20.7.3 PRODUCT PORTFOLIO 203
20.7.4 RECENT DEVELOPMENT 203
20.8 AKORN OPERATING COMPANY LLC 204
20.8.1 COMPANY SNAPSHOT 204
20.8.2 PRODUCT PORTFOLIO 204
20.8.3 RECENT DEVELOPMENT 204
20.9 AMNEAL PHARMACEUTICALS LLC. 205
20.9.1 COMPANY SNAPSHOT 205
20.9.2 REVENUE ANALYSIS 205
20.9.3 PRODUCT PORTFOLIO 206
20.9.4 RECENT DEVELOPMENTS 206
20.10 EYERIS VISIONCARE PVT. LTD. 207
20.10.1 COMPANY SNAPSHOT 207
20.10.2 PRODUCT PORTFOLIO 207
20.10.3 RECENT DEVELOPMENTS 207
20.11 MAYA BIOTECH PRIVATE LIMITED 208
20.11.1 COMPANY SNAPSHOT 208
20.11.2 PRODUCT PORTFOLIO 208
20.11.3 RECENT DEVELOPMENTS 208
20.12 OASIS MEDICAL 209
20.12.1 COMPANY SNAPSHOT 209
20.12.2 PRODUCT PORTFOLIO 209
20.12.3 RECENT DEVELOPMENTS 209
20.13 PRESTIGE CONSUMER HEALTHCARE INC. 210
20.13.1 COMPANY SNAPSHOT 210
20.13.2 REVENUE ANALYSIS 210
20.13.3 PRODUCT PORTFOLIO 211
20.13.4 RECENT DEVELOPMENT 211
20.14 SAGER PHARMA 212
20.14.1 COMPANY SNAPSHOT 212
20.14.2 PRODUCT PORTFOLIO 212
20.14.3 RECENT DEVELOPMENTS 212
20.15 SIMILASAN CORPORATION 213
20.15.1 COMPANY SNAPSHOT 213
20.15.2 PRODUCT PORTFOLIO 213
20.15.3 RECENT DEVELOPMENTS 213
20.16 SPECTRA VISION CARE 214
20.16.1 COMPANY SNAPSHOT 214
20.16.2 PRODUCT PORTFOLIO 214
20.16.3 RECENT DEVELOPMENTS 214
20.17 SYLENTIS 215
20.17.1 COMPANY SNAPSHOT 215
20.17.2 PRODUCT PORTFOLIO 215
20.17.3 RECENT DEVELOPMENT 215
20.18 THA LABORATORIES 216
20.18.1 COMPANY SNAPSHOT 216
20.18.2 PRODUCT PORTFOLIO 216
20.18.3 RECENT DEVELOPMENTS 216
20.19 WELLONA PHARMA 217
20.19.1 COMPANY SNAPSHOT 217
20.19.2 PRODUCT PORTFOLIO 217
20.19.3 RECENT DEVELOPMENTS 217
20.20 ZYDUS GROUP 218
20.20.1 COMPANY SNAPSHOT 218
20.20.2 REVENUE ANALYSIS 218
20.20.3 PRODUCT PORTFOLIO 219
20.20.4 RECENT DEVELOPMENTS 219
21 QUESTIONNAIRE 220
22 RELATED REPORTS 223
Segmentation
Short Description
Europe Pterygium Drug Market, Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (Russia, Spain, Turkey, Germany, Italy, United Kingdom, France, Hungary, Austria, Switzerland, Netherlands, Poland, Ireland, Norway, Lithuania, Rest of Europe) Industry Trends and Forecast to 2029
Market Definition:
Pterygium is a common ocular surface lesion that begins in the limbal conjunctiva within the palpebral fissure and progresses to the cornea. It is named after the Greek word pterygos, which means "wing". The lesion occurs more frequently at the nasal limbus than the temporal with a characteristic wing-like appearance. UV exposure is strongly linked to the occurrence of pterygia. Individuals having a history of elevated UV exposure and those living closer to the equator have a higher incidence (outdoor work). According to certain research, males have a somewhat higher incidence than females, which could be due to a higher rate of UV exposure.
It can cause redness, inflammation, and a change in the look of the eye; it can create astigmatism, which can cause blurry vision; and it can cause a whitish or pinkish growth covering the front of the eye. It could affect one or both eyes.
Pterygium is diagnosed using a microscope to examine the front components of the eye during a full eye examination and based on the appearance of tissue growth on the cornea from the white area of the eye.
Market Segmentation:
The Europe pterygium drug market is categorized into eight segments: disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel.
On the basis of disease type, the Europe pterygium drug market is segmented into progressive pterygium and atrophic pterygium
On the basis of stages, the Europe pterygium drug market is segmented into stage 2, stage 3, stage 1, and stage 4
On the basis of treatment, the Europe pterygium drug market is segmented into artificial tears/topical lubricants and steroid eye drops
On the basis of formulation, the Europe pterygium drug market is segmented into eye drops, eye ointments, and others
On the basis of mode of purchase, the Europe pterygium drug market is segmented into prescription and over-the-counter (OTC)
On the basis of population type, the Europe pterygium drug market is segmented into geriatric and adults
On the basis of end-user, the Europe pterygium drug market is segmented into hospitals, specialty clinics, home healthcare, and others
On the basis of distribution channel, the Europe pterygium drug market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others
Market Players
Some of the major players operating in the Europe pterygium drug market are:
Johnson & Johnson Services, Inc.
Novartis AG
Akorn Operating Company LLC
Bausch & Lomb Incorporated
AbbVie Inc.
Prestige Consumer Healthcare Inc.
Tha Laboratories
SAGER PHARMA
Bayer AG
Zydus Group
Similasan Corporation
Alcon
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.